NLNa Liu

Na Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Na Liu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Syndrome Differentiation and Treatment of Psoriasis by Traditional Chinese Medicines: An Integrating Study of Multi-Omics Analysis and Experimental Validation

    by Canzhe Li, Kaihao Chen, Yuanyuan Qiao, Peilin Wu, Chupeng Chen, Lvzhou Zhou, Yibing Yang, Jin Zhang, Na Liu, Chuanjun Shen, et al.

    The molecular basis underlying the clinical differentiation in treating psoriasis with syndromes of blood-heat or blood-stasis in traditional Chinese medicine remains unclear. This study employs an integrated multi-omics approach to explore the similarities and differences in the pathogenic mechanisms of these two syndromes, and to elucidate the molecular foundations of Compound Qingdai Capsule and Yinxiekang Pian, which are representative formulas for syndrome-specific treatment, thereby providing insights into the scientific connotation of syndrome differentiation and treatment. Multi-omics data were integrated with machine learning to identify genes differentiating the two syndromes of psoriasis. The therapeutic mechanisms were explored through network pharmacology and molecular docking. Finally, in vivo experiments involved constructing composite psoriasis models in SD rats by combining traditional Chinese medicine syndromes with imiquimod induction, and analyzing skin lesion tissues via qPCR and ELISA. After constructing the psoriasis pathway network and successfully establishing rat models, the research identified the characteristic genes of blood-heat syndrome psoriasis as GSK3B, MTOR and CDK4, and those of blood-stasis syndrome psoriasis as AKT1, TNF and STAT3. STAT1 was found to be a common characteristic gene of both syndromes, while LTBP1, PROS1, and ALDH16A1 were the differential genes for distinguishing the two syndromes. Finally, Compound Qingdai Capsule and Yinxiekang Pian were shown to reduce the mRNA and protein expressions of GSK3B, AKT1 and STAT1 to varying degrees. GSK3B and AKT1 are differentially expressed in blood-heat syndrome and blood-stasis syndrome psoriasis respectively, while STAT1 is a common inflammatory mediator for both. Compound Qingdai Capsule and Yinxiekang Pian respectively provide a theoretical basis for traditional Chinese medicine syndrome differentiation and treatment of psoriasis by intervening in the same or different inflammatory targets and signaling pathways.


  • Open Access

    Multi-Target Mechanism of Compound Qingdai Capsule for Treatment of Psoriasis: Multi-Omics Analysis and Experimental Verification

    by Yuanyuan Qiao, Canzhe Li, Chupeng Chen, Peilin Wu, Yibing Yang, Mingxiang Xie, Na Liu, Jiangyong Gu

    Background: Psoriasis is a chronic skin disease affected by genetic and autoimmunity. The traditional Chinese medicine, Compound Qingdai Capsule (CQC), has shown potential benefits in treating psoriasis in clinical settings. Despite its efficacy, the molecular mechanisms underpinning its therapeutic action remain unclear. Purpose: This study aimed to unravel the molecular mechanism of Compound Qingdai Capsule for psoriasis based on the psoriasis pathogenic pathway network, integrating multi-omics analysis, systems pharmacology, machine learning modeling, and animal experimentation. Methods: Psoriasis pathogenic pathway network was constructed through employing bioinformatics analysis and psoriasis-related multi-omics data mining. The ingredients of CQC were detected by UPLC-MS/MS, and target prediction was performed by systems pharmacology. Machine learning, including Lasso regression, Random Forest, and Support Vector Machine (SVM), were utilized to screen core targets of psoriasis. Molecular docking was employed to evaluate the binding affinity between ingredients and core targets. The expression levels of core targets were determined using qRT-PCR and ELISA. Results: Psoriasis-related datasets GSE201827 and GSE174763 were comprehensively analyzed to obtain 635 psoriasis-related genes. These genes were further enriched to elucidate signaling pathways involved, leading to the construction of psoriasis pathogenic pathway network. Utilizing UPLC-MS/MS, 29 main ingredients of CQC were characterized. CQC ingredients-targets network was constructed using these ingredients and their targets. Screening of CQC anti-psoriasis core targets using machine learning algorithm. Molecular docking confirmed good binding affinity between these targets and ingredients. Imiquimod (IMQ) induced psoriasis-like rat validated the anti-psoriasis effect of CQC by alleviating symptoms, reducing spleen and thymus index, and modulating the expressions of core targets at mRNA and protein levels. Conclusion: CQC effectively modulates the expression levels of AURKB, CCNB1, CCNB2, CCNE1, CDK1, and JAK3 through various ingredients, such as astilbin, salvianolic acid A, and engeletin, via multiple pathways, thereby alleviating psoriasis-like symptoms.


  • Open Access

    Integrated Bioinformatics Analysis and Cellular Experimental Validation Identify Lipoprotein Lipase Gene as a Novel Biomarker for Tumorigenesis and Prognosis in Lung Adenocarcinoma

    by Wanwan He, Meilian Wei, Yan Huang, Junsen Qin, Meng Liu, Na Liu, Yanli He, Chuanbing Chen, Yali Huang, Heng Yin, et al.

    Lung adenocarcinoma (LUAD) is one of the leading causes of death worldwide, and thus, more biomarker and therapeutic targets need to be explored. Herein, we aimed to explore new biomarkers of LUAD by integrating bioinformatics analysis with cell experiments. We firstly identified 266 druggable genes that were significantly differentially expressed between LUAD tissues and adjacent normal lung tissues. Among these genes, SMR analysis with p-value correction suggested that declining lipoprotein lipase (LPL) levels may be causally associated with an elevated risk of LUAD, which was corroborated by co-localization analysis. Analyses of clinical data showed that LPL in lung cancer tissues has considerable diagnostic value for LUAD, and elevated LPL levels were positively associated with improved patient survival outcomes. Cell experiments with an LPL activator proved these findings; the activator inhibited the proliferation and migration of lung cancer cells. Next, we found that LPL promoted the infiltration of immune cells such as DCs, IDCs, and macrophages in LUAD by mononuclear sequencing analysis and TIMER2.0. Meanwhile, patients with low levels of LPL expression demonstrated superior immunotherapeutic responses to anti-PD-1 therapy. We conclude that LPL acts as a diagnostic and prognostic marker for LUAD.


  • Molecular mechanism of PSORI-CM01 for psoriasis by regulating the inflammatory cytokines network

    by Mingxiang Xie, Miaomiao Zhang, Yuanyuan Qiao, Yibing Yang, Fuda Xie, Lichun Chen, Na Liu, Jiangyong Gu


  • Pathway network-based quantitative modeling of the time-dependent and dose-response anti-inflammatory effect of Reduning Injection

    by Fuda Xie, Mingxiang Xie, Yibing Yang, Weizhen Ao, Tingxiu Zhao, Na Liu, Bonan Chen, Wei Kang, Wei Xiao, Jiangyong Gu


  • Study on the mechanism of Cortex Lycii on lung cancer based on network pharmacology combined with experimental validation

    by Zhenhui Guo, Heng Yin, Tong Wu, Shaofeng Wu, Lingyun Liu, Lei Zhang, Yanli He, Ren Zhang, Na Liu